title: p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis.
abstract: The aim of this study was to evaluate, in a prospective study, the predictive role of p53 status analysed at four different levels in identifying the response to preoperative radiotherapy in rectal adenocarcinoma. Before treatment, 70 patients were staged and endoscopic forceps biopsies from the tumour area were taken. p53 status was assessed by total cDNA sequencing, allelic loss analysis, immunohistochemistry, and p53 antibodies. Neoadjuvant treatment was based on preoperative radiotherapy or radiochemotherapy. Response to therapy was evaluated after surgery by both pathologic downstaging and histologic tumour regression grade. In all, 35 patients (50.0%) had p53 gene mutations; 44.4% of patients had an allelic loss; nuclear p53 overexpression was observed in 39 patients (55.7%); and p53 antibodies were detected in 11 patients (16.7%). In the multilevel analysis of p53 status, gene mutations correlated with both nuclear protein overexpression (P < 0.0001) and loss of heterozygosity (P = 0.013). In all, 29 patients (41.4%) were downstaged by pathologic analysis, and 19 patients (29.2%) were classified as tumour regression grade 1. Whatever the method of evaluation of treatment response, no correlation between p53 alterations and response to radiotherapy was observed. Our results do not support the use of p53 alterations alone as a predictive marker for response to radiotherapy in rectal carcinoma.
authors.affiliation: Cancer Research Center, Val d'Aurelle Cancer Institute, Montpellier 34298, France. ecrapez@valdorel.fnclcc.fr
authors.forename: E
authors.initials: E
authors.lastname: Lopez-Crapez
authors.forename: F
authors.initials: F
authors.lastname: Bibeau
authors.forename: S
authors.initials: S
authors.lastname: Thézenas
authors.forename: M
authors.initials: M
authors.lastname: Ychou
authors.forename: J
authors.initials: J
authors.lastname: Simony-Lafontaine
authors.forename: A
authors.initials: A
authors.lastname: Thirion
authors.forename: D
authors.initials: D
authors.lastname: Azria
authors.forename: J
authors.initials: J
authors.lastname: Grenier
authors.forename: P
authors.initials: P
authors.lastname: Senesse
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D003082:Colectomy; D005260:Female; D016158:Genes, p53; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D016159:Tumor Suppressor Protein p53